Moderna (NASDAQ:MRNA) Stock Price Down 3.4% Following Insider Selling

Shares of Moderna, Inc. (NASDAQ:MRNA) dropped 3.4% during trading on Monday after an insider sold shares in the company. The company traded as low as $120.38 and last traded at $120.72. Approximately 923,799 shares changed hands during mid-day trading, a decline of 77% from the average daily volume of 4,102,888 shares. The stock had previously closed at $125.00.

Specifically, CFO James M. Mock sold 647 shares of the stock in a transaction on Thursday, February 29th. The shares were sold at an average price of $94.57, for a total transaction of $61,186.79. Following the transaction, the chief financial officer now directly owns 4,300 shares in the company, valued at approximately $406,651. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Moderna news, CFO James M. Mock sold 647 shares of the company’s stock in a transaction that occurred on Thursday, February 29th. The stock was sold at an average price of $94.57, for a total transaction of $61,186.79. Following the sale, the chief financial officer now owns 4,300 shares in the company, valued at $406,651. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, President Stephen Hoge sold 2,388 shares of Moderna stock in a transaction that occurred on Thursday, February 29th. The stock was sold at an average price of $94.57, for a total value of $225,833.16. Following the completion of the transaction, the president now owns 1,515,898 shares of the company’s stock, valued at approximately $143,358,473.86. The disclosure for this sale can be found here. Over the last quarter, insiders sold 139,954 shares of company stock worth $14,822,576. Insiders own 15.20% of the company’s stock.

Analyst Upgrades and Downgrades

MRNA has been the subject of several research reports. Canaccord Genuity Group lifted their price target on shares of Moderna from $91.00 to $106.00 and gave the company a “hold” rating in a report on Friday, May 3rd. William Blair restated a “market perform” rating on shares of Moderna in a research note on Monday, April 1st. Royal Bank of Canada increased their price target on Moderna from $125.00 to $135.00 and gave the stock an “outperform” rating in a research report on Friday, May 3rd. UBS Group boosted their price objective on Moderna from $143.00 to $151.00 and gave the company a “buy” rating in a research report on Tuesday. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $125.00 target price on shares of Moderna in a research report on Tuesday, April 9th. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, Moderna currently has a consensus rating of “Hold” and a consensus target price of $126.89.

Moderna Stock Down 0.9 %

The firm’s fifty day moving average is $106.10 and its two-hundred day moving average is $95.05. The firm has a market cap of $46.40 billion, a price-to-earnings ratio of -7.73 and a beta of 1.57. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.03 and a quick ratio of 3.91.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings results on Thursday, May 2nd. The company reported ($3.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.59) by $0.52. The company had revenue of $167.00 million during the quarter, compared to analyst estimates of $93.26 million. Moderna had a negative net margin of 115.82% and a negative return on equity of 20.10%. The business’s revenue for the quarter was down 91.0% compared to the same quarter last year. During the same period in the prior year, the business posted $0.19 EPS. On average, sell-side analysts expect that Moderna, Inc. will post -7.47 EPS for the current fiscal year.

Institutional Investors Weigh In On Moderna

Institutional investors have recently added to or reduced their stakes in the company. Ogorek Anthony Joseph NY ADV bought a new stake in shares of Moderna in the 4th quarter worth $27,000. Arlington Trust Co LLC boosted its stake in Moderna by 4,833.3% during the fourth quarter. Arlington Trust Co LLC now owns 296 shares of the company’s stock valued at $29,000 after buying an additional 290 shares in the last quarter. Westside Investment Management Inc. acquired a new position in Moderna during the first quarter worth about $32,000. Rise Advisors LLC raised its position in Moderna by 953.3% in the first quarter. Rise Advisors LLC now owns 316 shares of the company’s stock worth $34,000 after acquiring an additional 286 shares in the last quarter. Finally, UMB Bank n.a. lifted its holdings in Moderna by 121.8% in the 1st quarter. UMB Bank n.a. now owns 366 shares of the company’s stock valued at $39,000 after acquiring an additional 201 shares during the last quarter. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.